Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · Real-Time Price · USD
34.06
+0.34 (1.01%)
At close: May 29, 2025, 4:00 PM
34.05
-0.01 (-0.03%)
After-hours: May 29, 2025, 4:04 PM EDT
HRMY Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for HRMY stock ranges from a low of $40 to a high of $70. The average analyst price target of $53.38 forecasts a 56.72% increase in the stock price over the next year.
Price Target: $53.38 (+56.72%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for HRMY stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Maintains $44 → $48 | Buy | Maintains | $44 → $48 | +40.93% | May 15, 2025 |
| Needham | Needham | Strong Buy Reiterates $49 | Strong Buy | Reiterates | $49 | +43.86% | May 7, 2025 |
| Needham | Needham | Strong Buy Reiterates $49 | Strong Buy | Reiterates | $49 | +43.86% | May 6, 2025 |
| UBS | UBS | Strong Buy Maintains $55 → $48 | Strong Buy | Maintains | $55 → $48 | +40.93% | Apr 28, 2025 |
| Needham | Needham | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +46.80% | Apr 10, 2025 |
Financial Forecast
Revenue This Year
860.16M
from 714.73M
Increased by 20.35%
Revenue Next Year
1.01B
from 860.16M
Increased by 17.42%
EPS This Year
3.28
from 2.51
Increased by 30.68%
EPS Next Year
4.34
from 3.28
Increased by 32.30%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 898.1M | 1.1B | 1.4B | ||
| Avg | 860.2M | 1.0B | 1.2B | ||
| Low | 820.6M | 915.1M | 1.0B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 25.7% | 28.0% | 39.1% | ||
| Avg | 20.3% | 17.4% | 20.8% | ||
| Low | 14.8% | 6.4% | 0.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.04 | 5.24 | 7.81 | ||
| Avg | 3.28 | 4.34 | 5.76 | ||
| Low | 2.13 | 2.77 | 4.38 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 61.1% | 59.7% | 80.0% | ||
| Avg | 30.7% | 32.3% | 32.8% | ||
| Low | -15.3% | -15.4% | 1.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.